Dose-response relationship of inhaled budesonide in adult asthma: A meta-analysis

European Respiratory Journal

Volumn 23, Issue 4, 2004, Pages 552-558

  Masoli, M ^a   Holt, S ^b   Weatherall, M ^c   Beasley, Richard ^a,d  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b P3 Research   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Adults; Asthma; Budesonide; Dose response; Inhaled corticosteroids; Meta analysis

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; PLACEBO;

ADOLESCENT; ADULT; AGE; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; INHALATION SPACER; MAJOR CLINICAL STUDY; META ANALYSIS; METERED DOSE INHALER; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; PUBLICATION; QUALITATIVE ANALYSIS; REGRESSION ANALYSIS; STATISTICAL MODEL; TURBUHALER; VARIANCE;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FORCED EXPIRATORY VOLUME; HUMANS; NEBULIZERS AND VAPORIZERS; PEAK EXPIRATORY FLOW RATE; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 1842533220     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.04.00076604     Document Type: Article

References (37)

1. Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: Meta-analysis. BMJ 2001; 323: 253-256.
2. British Thoracic Society & Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Thorax 2003; 58; Suppl. 1, i1-i94.
3. National Heart, Lung and Blood Institute, National Institutes for Health. Global strategy for asthma management and prevention: NHLBI/WHO Workshop Report. Bethseda, Maryland, National Institutes of Health, 1996.
4. British Medical Assoiation, Royal Pharmaceutical Society of Great Britain. British National Formulary. London, BMA, RPS, 2000; pp. 147 (No.40).
5. Herxheimer A. Commentary: Dosage needs systematic and critical review. BMJ 2001; 323: 257.
6. Thorsson L, Edsbacker S. Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer. Eur Respir J 1998; 12: 1340-1345.
7. Thorsson L. Studies on the deposition, bioavailability and systemic activity of glucocorticoids in man (thesis). University Hospital, Lund, 1998.
8. Johnson ES, Lanes SF, Wentworth CE, Satterfield MH, Abebe BL, Dicker LA. A meta-regression analysis of the dose-response effect of aspirin on stroke. Arch Int Med 1999; 159: 1248-1253.
9. Sutton AJ, Abrams K, Jones D, Sheldon T, Son F. Methods for Meta-analysis in Medical Research. Chichester, John Wiley & Sons Ltd, 2000.
10. D'Agostino RB, Weintraub M. Meta-analysis: A method for synthesizing research. Clin Pharmacol Ther 1995; 58: 605-616.
11. Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered by turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy, Clin Immunol 1998; 101: 457-463.
12. Kemp J, Wanderer A, Ramsdell J, et al. Rapid onset of control with budesonide turbuhaler in patients with mild to moderate asthma. Ann Allergy, Asthma Immunol 1999; 82: 463-471.
13. Miyamoto T, Takahashi T, Nakajima S, et al. A double blind, placebo-controlled dose-response study with budesonide turbuhaler in Japanese asthma patients. Respirology 2000: 3: 247-256.
14. Lorentzson S, Boe J, Eriksson G, Persson G. Use of inhaled corticosteroids in patients with mild asthma. Thorax 1990; 45: 733-735.
15. O'Byrne P, Cuddy L, Taylor D, Birch S, Morris J, Syrotuik J. Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice. Can Respir J 1996; 3: 169-175.
16. Pirozynski M, Kulaga Z, Karlstrom R. Pulmicort turbuhaler in mild to moderate asthma: Comparison of initial high dose, constant low dose and placebo. Am J Resp Crit Care Med 1996; 153: A343.
17. Barnes N, Hallett C, Harris A. Clinical experience with fluticasone propionate in asthma: A meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Resp Med 1998; 92: 95-104.
18. McKenzie A. Percutaneous absorption of steroids. Arch Derm 1962; 86: 91-94.
19. McKenzie A. Method for comparing percutaneous absorption of steroids. Arch Derm 1962; 86: 88-90.
20. Busse W, Brazinsky S, Jacobson, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 104: 215-222.
21. Reddel H, Jenkins C, Marks G, et al. Optimal asthma control starting with high doses of inhaled budesonide. Eur Respir J 2000; 16: 226-235.
22. Chanez P, Karlstrom R, Godard P. High or standard initial dose of budesonide to control mild to moderate asthma. Eur Respir J 2001; 17: 856 862.
23. Tukiainen H, Taivainen A, Majander R, et al. Comparison of high and low dose of the inhaled steroid budesonide as initial treatment in newly detected asthma. Res Med 2000; 94: 678-683.
24. Rees T, Lennox B, Timney A, Houssain M, Turbitt M, Richardson P. Comparison of increasing the dose of budesonide to 800 μg/day with a maintained dose of 400 μg/day in mild to moderate asthmatic patients. Eur J Clin Res 1993; 4: 67-77.
25. Pauwels RA, Lofdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma (FACET). N Engl J Med 1997; 337: 1405-1411.
26. O'Byrne P, Barnes P, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma (OPTIMA). Am J Respir Crit Care Med 2001; 164: 1392-1397.
27. Foresi A, Cristina Morelli M, Catena E. Low dose budesonide with the addition of an increased dose during exacerbations in long term asthma control. Chest 2000; 117: 440-446.
28. Van der Molen T, Meyboom-De Jong B, Mulder H, Postma D. Starting with a higher dose of inhaled corticosteroids in primary care asthma treatment. Am J Respir Crit Care Med 1998; 158: 121-125.
29. Nana A, Youngchaiyud P, Charoenratanakul S, et al. High-dose inhaled budesonide may substitute for oral therapy after an acute asthma attack. J Asthma 1998; 35: 647-655.
30. Edmonds ML, Carmargo CR Jr, Brenner BE, Rowe BH. Inhaled steroids for acute asthma following emergency department discharge. Cochrane Database Syst Rev 2000; 3: CD002316.
31. Miyamoto T, Takahashi T, Nakajima S, et al. A double blind, placebo-controlled steroid-sparing study with budesonide turbuhaler in Japanese oral steroid-dependent asthma patients. Respirology 2000; 5: 231-240.
32. Laursen L, Taudorf E, Weeke B. High dose inhaled budesonide in treatment of severe steroid-dependent asthma. Eur J Resp Dis 1986; 68: 19-28.
33. Nelson H, Berstein L, Fink J, et al. Oral glucocorticosteroid-sparing effect of budesonide administered by turbuhaler. Chest 1998; 113: 1264-1271.
34. Barnes PJ, Pederson S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Resp Crit Care Med 1998; 157: S1-S53.
35. Kamada A, Szefler S, Martin R, et al. Issues in the use of inhaled glucocorticoids. Am J Respir Crit Care Med 1996; 153: 1739-1748.
36. Aaronson D, Kaiser H, Dockhorn R, et al. Effects of budesonide by means of the turbuhaler on the hypothalamic-pituitary-adrenal axis in asthmatic subjects: A dose-response study. J Allergy Clin Immunol 1998; 101: 312-319.
37. Wong C, Walsh L, Smith C, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000; 355: 1399 1403.